argenx SE American Depositary Shares (ARGX) Stock Price

ARGXStock

$819.14+2.59%52W

Market Cap$51.51B

P/E41.50x

PEG Ratio1.01

Div yield—

Beta1.54

ARGX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-8.54%

Price vs S&P 500 (4W)-14.85%

PEG Ratio1.01

VGM Score61.32

P/E Ratio (Annual)41.50x

P/CF (Annual)78.25x

Book Value / Share (Quarterly)$134.59

P/TBV (Annual)7.00x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)116.21%

Cash Flow / Share (Quarterly)$13.11

Price vs S&P 500 (YTD)-9.05%

Gross Margin (TTM)89.79%

Net Profit Margin (TTM)30.59%

EPS (TTM)$37.84

10-Day Avg Trading Volume0.13M

EPS Excl Extra (TTM)$37.84

Revenue Growth (5Y)151.52%

EPS (Annual)$19.57

ROI (Annual)17.53%

Gross Margin (Annual)89.14%

Net Profit Margin (5Y Avg)-41.95%

Cash / Share (Quarterly)$82.89

P/E Basic Excl Extra (TTM)21.66x

Revenue Growth QoQ (YoY)59.71%

P/E Normalized (Annual)41.50x

ROA (Last FY)14.88%

Revenue Growth TTM (YoY)165.21%

EBITD / Share (TTM)$24.51

ROE (5Y Avg)-3.15%

Operating Margin (TTM)28.27%

Cash Flow / Share (Annual)$9.27

P/B Ratio6.37x

P/B Ratio (Quarterly)6.74x

Net Income / Employee (Annual)$808,000

EV / Revenue (TTM)8.84x

Net Interest Coverage (TTM)-81.88x

ROA (TTM)18.86%

EPS Growth QoQ (YoY)102.60%

EV / EBITDA (TTM)31.80x

EPS Incl Extra (Annual)$19.57

Current Ratio (Annual)5.23x

Quick Ratio (Quarterly)4.52x

3-Month Avg Trading Volume0.09M

52-Week Price Return2.59%

EV / Free Cash Flow (Annual)87.32x

P/E Incl Extra (TTM)21.66x

Revenue / Employee (TTM)$5,060,200

Tangible BV / Share (Quarterly)$130.34

P/S Ratio (Annual)12.91x

Asset Turnover (Annual)0.48x

52-Week High$925.00

Operating Margin (5Y Avg)-51.15%

EPS Excl Extra (Annual)$19.57

CapEx CAGR (5Y)85.11%

Tangible BV CAGR (5Y)36.16%

26-Week Price Return1.37%

Quick Ratio (Annual)4.62x

13-Week Price Return-3.45%

Total Debt / Equity (Annual)0.01x

Current Ratio (Quarterly)5.12x

Enterprise Value$50.08B

Revenue / Share Growth (5Y)133.37%

Asset Turnover (TTM)0.61x

Book Value / Share Growth (5Y)27.45%

Revenue / Employee (Annual)$2,596,200

Inventory Turnover (Annual)1.02x

Pretax Margin (Annual)30.80%

Cash / Share (Annual)$71.75

3-Month Return Std Dev55.45%

Net Income / Employee (TTM)$1,548,000

EBITDA Interim CAGR (5Y)38.90%

ROE (Last FY)17.64%

Net Interest Coverage (Annual)5.58x

EPS Basic Excl Extra (Annual)$19.57

P/FCF (TTM)65.41x

Receivables Turnover (TTM)5.47x

EV / Free Cash Flow (TTM)61.09x

Total Debt / Equity (Quarterly)0.01x

EPS Incl Extra (TTM)$37.84

Receivables Turnover (Annual)3.60x

ROI (TTM)22.29%

P/S Ratio (TTM)6.63x

Pretax Margin (5Y Avg)-49.62%

Revenue / Share (Annual)$62.87

Tangible BV / Share (Annual)$113.94

Forward P/E27.00x

Price vs S&P 500 (52W)-12.94%

P/E Ratio (TTM)21.66x

EPS Growth TTM (YoY)95.72%

Year-to-Date Return1.51%

5-Day Price Return-0.76%

EPS Normalized (Annual)$19.57

ROA (5Y Avg)-3.03%

Net Profit Margin (Annual)31.12%

Month-to-Date Return-14.08%

EBITD / Share (Annual)$16.26

Operating Margin (Annual)25.38%

LT Debt / Equity (Annual)0.32x

P/CF (TTM)55.03x

ROI (5Y Avg)-3.15%

P/E Excl Extra (TTM)21.66x

EPS Basic Excl Extra (TTM)$37.84

P/TBV (Quarterly)6.96x

P/B Ratio (Annual)6.74x

Inventory Turnover (TTM)2.32x

Pretax Margin (TTM)32.41%

Book Value / Share (Annual)$118.34

Price vs S&P 500 (13W)-6.14%

Beta1.54x

P/FCF (Annual)93.48x

Revenue / Share (TTM)$129.54

ROE (TTM)22.43%

52-Week Low$568.40

vGradeD

gGradeA

mGradeB

vgmGradeB

ARGX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Jul 23, 2026	$6.19	$7.32	+18.17%(+$1.13)
Q1 2026	May 7, 2026	$4.92	$5.52	+12.12%(+$0.60)
Q4 2025	Feb 26, 2026	$6.11	$8.02	+31.24%(+$1.91)
Q3 2025	Oct 30, 2025	$4.16	$5.18	+24.47%(+$1.02)
Q2 2025	Jul 31, 2025	$3.02	$3.74	+23.97%(+$0.72)

ARGX Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.24

4.20

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	B	168.6x	-19.0%	—	—	$17.17

About argenx SE American Depositary Shares

Argenx is a Dutch biopharmaceutical company developing antibody-based therapies for rare autoimmune and immune-mediated diseases. Its lead product, Vyvgart (efgartigimod), is FDA-approved for generalized myasthenia gravis, with the subcutaneous formulation Vyvgart Hytrulo also approved for chronic inflammatory demyelinating polyneuropathy. The company's pipeline includes candidates for primary immune thrombocytopenia, thyroid eye disease, and Sjögren's disease.